Drugs / human recombined granulocyte-macrophage colony stimulating factor
human recombined granulocyte-macrophage colony stimulating factor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02976740 | Nov 2016 → Jun 2019 | lung cancer | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human recombined granulocyte-macrophage colony stimulating factor | “Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle.” NCT02976740 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day)” NCT02976740 ↗ |